XTX Topco Ltd Acquires New Position in MiMedx Group, Inc. (NASDAQ:MDXG)

XTX Topco Ltd bought a new position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 40,120 shares of the company's stock, valued at approximately $386,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in shares of MiMedx Group in the 4th quarter valued at $887,000. Renaissance Technologies LLC boosted its position in MiMedx Group by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after buying an additional 280,327 shares during the period. Cannell Capital LLC grew its stake in shares of MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after buying an additional 40,235 shares during the last quarter. Invesco Ltd. increased its holdings in shares of MiMedx Group by 2.2% in the fourth quarter. Invesco Ltd. now owns 56,565 shares of the company's stock worth $544,000 after buying an additional 1,226 shares during the period. Finally, Trexquant Investment LP lifted its stake in shares of MiMedx Group by 29.7% in the 4th quarter. Trexquant Investment LP now owns 221,262 shares of the company's stock valued at $2,129,000 after acquiring an additional 50,635 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Stock Up 2.0 %

Shares of NASDAQ:MDXG opened at $6.68 on Wednesday. The stock's 50-day moving average is $7.62 and its 200 day moving average is $8.03. The company has a market cap of $984.40 million, a PE ratio of 12.15 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analysts' expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on MDXG. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, April 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Buying and Selling at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This trade represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.30% of the stock is currently owned by company insiders.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.